Literature DB >> 9637512

Structural and functional analysis of J chain-deficient IgM.

E J Wiersma1, C Collins, S Fazel, M J Shulman.   

Abstract

Previous studies have discerned two forms of polymeric mouse IgM: moderately cytolytic (complement-activating) pentamer, which contains J chain, and highly cytolytic hexamer, which lacks J chain. To investigate the relationships among polymeric structure, J chain content, and cytolytic activity, we produced IgM in J chain-deficient and J chain-proficient mouse hybridoma cell lines. Both hexamer and pentamer were produced in the absence as well as the presence of J chain. Hexameric IgM activated (guinea pig) complement approximately 100-fold more efficiently than did J chain-deficient pentamer, which, in turn, was more active than J chain-containing pentamer. These results are consistent with the hypothesis that J chain-containing pentamer cannot activate complement. We also analyzed the structure of IgM-S337, in which the mu-chain bears the C337S substitution. Like normal IgM, IgM-S337 was formed as a hexamer and as both J chain deficient- and J chain-containing pentamers. Unlike normal IgM, IgM-S337 dissociated in SDS into various subunits. For IgM-S337 pentamer, the predominant subunits migrated as mu2kappa2 and mu4kappa4, and the subunit distribution was unaltered by J chain. However, J chain was found only in the mu2kappa2 species, suggesting that some arrangement of inter-mu bonds directs incorporation of J chain. IgM-S337 hexamer also dissociated to mu2kappa2 and mu4kappa4, but also yielded several species migrating much more slowly in SDS-PAGE than wild-type mu12kappa12. To account for these forms, we propose that each mu-chain can interact with three other mu-chains and that some hexameric molecules contain two catenated mu6kappa6 circles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637512

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  Antigenic specificity and expression of a natural idiotope on human pentameric and hexameric IgM polymers.

Authors:  Vladimir Petrušić; Irena Zivković; Marijana Stojanović; Ivana Stojićević; Emilija Marinković; Aleksandra Inić-Kanada; Ljiljana Dimitijević
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

3.  TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

Authors:  Xiuhong Piao; Tatsuhiko Ozawa; Hiroshi Hamana; Kiyomi Shitaoka; Aishun Jin; Hiroyuki Kishi; Atsushi Muraguchi
Journal:  Oncoimmunology       Date:  2016-05-04       Impact factor: 8.110

4.  High level expression of functional human IgMs in human PER.C6 cells.

Authors:  Anna Tchoudakova; Frank Hensel; Alec Murillo; Bernie Eng; Marketa Foley; Lakee Smith; Frank Schoenen; Antonia Hildebrand; Arndt-René Kelter; Leodevico L Ilag; H Peter Vollmers; Stephanie Brandlein; Jane McIninch; John Chon; Gene Lee; Marco Cacciuttolo
Journal:  MAbs       Date:  2009-03-24       Impact factor: 5.857

5.  Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM.

Authors:  Edward S X Moh; Chi-Hung Lin; Morten Thaysen-Andersen; Nicolle H Packer
Journal:  J Am Soc Mass Spectrom       Date:  2016-04-01       Impact factor: 3.109

6.  Induction of mucosal immunity in the avian Harderian gland with a replication-deficient Ad5 vector expressing avian influenza H5 hemagglutinin.

Authors:  Frederik W van Ginkel; De-chu C Tang; Stephen L Gulley; Haroldo Toro
Journal:  Dev Comp Immunol       Date:  2009       Impact factor: 3.636

7.  Multi-Dimensional Measurement of Antibody-Mediated Heterosubtypic Immunity to Influenza.

Authors:  Jiong Wang; Shannon P Hilchey; Ollivier Hyrien; Nelson Huertas; Sheldon Perry; Manojkumar Ramanunninair; Doris Bucher; Martin S Zand
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

8.  The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein.

Authors:  Emiri Hiramoto; Akihisa Tsutsumi; Risa Suzuki; Shigeru Matsuoka; Satoko Arai; Masahide Kikkawa; Toru Miyazaki
Journal:  Sci Adv       Date:  2018-10-10       Impact factor: 14.136

9.  The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding.

Authors:  Wai-Heng Lua; Wei-Li Ling; Joshua Yi Yeo; Jun-Jie Poh; David Philip Lane; Samuel Ken-En Gan
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

10.  Site-Specific N-Glycan Characterization of Grass Carp Serum IgM.

Authors:  Yi-Ling Su; Bing Wang; Meng-Die Hu; Zheng-Wei Cui; Jian Wan; Hao Bai; Qian Yang; Yan-Fang Cui; Cui-Hong Wan; Li Xiong; Yong-An Zhang; Hui Geng
Journal:  Front Immunol       Date:  2018-11-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.